SNDX
Syndax Pharmaceuticals Inc
NASDAQ · Healthcare · Biotechnology · US
$10.33
−27.72%Nov 4, 2026, 14:00 UTC
Syndax Pharmaceuticals Inc announced that 19 abstracts on Revuforj (revumenib) and Niktimvo (axatilimab-csfr) were accepted for presentation at ASH 2026, including seven oral presentations.
Source:Nov 2, 2026, 23:56 UTC
Syndax Pharmaceuticals Inc reported a third-quarter loss of $0.55 per share, compared with a loss of $0.70 per share a year earlier.
Source:Nov 2, 2026, 21:01 UTC
Syndax Pharmaceuticals Inc reported third-quarter 2026 total revenue of $83.3 million, up 82% year over year, including Revuforj net revenue of $60.7 million and Niktimvo net revenue of $67.4 million.
Source:Nov 2, 2026, 21:01 UTC
Syndax Pharmaceuticals Inc appointed Aaron A. Ondrey as chief financial officer, effective November 9, 2026, as Keith A. Goldan retires from the role and remains with the company through year-end to support the transition.
Source:Oct 30, 2026, 13:01 UTC
Syndax Pharmaceuticals Inc said its Revuforj (revumenib) won the 2026 Prix Galien USA award for Best Product for Rare/Orphan Diseases.
Source:Oct 26, 2026, 11:00 UTC
Syndax Pharmaceuticals Inc announced that it will report its third-quarter 2026 financial results and provide a business update on November 2, 2026.
Source:Oct 14, 2026, 14:56 UTC
Syndax Pharmaceuticals Inc shares fell 16%.
Source:Oct 14, 2026, 02:17 UTC
Syndax Pharmaceuticals Inc shares fell more than 11% after its Phase 2 MAXPIRe trial of axatilimab missed its primary endpoint in idiopathic pulmonary fibrosis.
Source:Oct 13, 2026, 14:43 UTC
Syndax Pharmaceuticals Inc said it would not continue developing axatilimab for idiopathic pulmonary fibrosis.
Oct 13, 2026, 12:02 UTC
Syndax Pharmaceuticals Inc shares fell sharply in pre-market trading.
Source:Oct 12, 2026, 20:01 UTC
Syndax Pharmaceuticals Inc announced that its MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis did not meet the primary endpoint of annualized forced vital capacity decline; the treatment was well tolerated, with no new safety signals.
Oct 2, 2026, 20:01 UTC
Syndax Pharmaceuticals granted inducement stock options to purchase up to 213,300 shares of common stock to nine new employees on October 1, 2026.
Source:Aug 4, 2026, 20:01 UTC
Syndax Pharmaceuticals reported second quarter 2026 financial results, with total revenue of $73 million, a 92% year-over-year increase.
Jul 14, 2026, 20:03 UTC
Syndax Pharmaceuticals introduced two pipeline assets aimed at non-small cell lung cancer and myelofibrosis at a company R&D event.
Source:Jun 10, 2026, 00:00 UTC
Syndax Pharmaceuticals issued $250.0 million of 2.25% Convertible Senior Notes due 2031, with net proceeds of approximately $243.0 million for general corporate purposes.
Jun 4, 2026, 00:00 UTC
Syndax Pharmaceuticals Inc completed a private placement of $250 million 2.25% convertible senior notes due 2031 on June 10, 2026.
Source: